Several reports mention that statin (HMG-CoA reductase inhibitor) use seems to be associated with several neurologic disorders and that the lipid-lowering effect of statins may contribute to some neural toxicity.
This study aimed to evaluate the association between statin use and Bell’s palsy using a population-based health insurance database.
This case-control study identified 1,977 subjects with Bell’s palsy as cases and 5,931 sex- and age-matched subjects without Bell’s palsy as controls from the Taiwan Longitudinal Health Insurance Database 2000. Conditional logistic regressions was used to estimate the odds ratio (OR) and 95 % confidence interval (CI) for previous use of statins between the cases and controls. The associations of regular and irregular statin users with Bell’s palsy were further analyzed.
By Chi-square test, there was a significant difference in the prevalence of statin use between cases and controls (23.2 vs. 16.4 %, p < 0.001). Conditional logistic regression analysis revealed that after adjusting for diabetes mellitus, hypertension, and hyperlipidemia, the OR for prior statin use was 1.47 (95 % CI 1.28–1.69) for cases compared with controls. Bell’s palsy was significantly associated with previous regular statin use (≥60 days within 6 months) (adjusted OR: 1.46, 95 % CI 1.28–1.67). However, there was no increased adjusted OR of irregular statin use (<60 days within 6 months) for cases compared with controls (OR: 1.09, 95 % CI 0.82–1.46).
Our present data suggest a potential association between regular statin use and Bell’s palsy.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
Prospective Studies Collaboration, Lewington S, Whitlock G, Clarke R, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370(9602):1829–39.
Goldstein JL, Hazzard WR, Schrott HG, et al. Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction. J Clin Invest. 1973;52(7):1533–43.
Cohn PF, Gabbay SI, Weglicki WB. Serum lipid levels in angiographically defined coronary artery disease. Ann Intern Med. 1976;84(3):241–5.
Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011;(1):CD004816.
Chang CH, Lee YC, Tsai CT, et al. Continuation of statin therapy and a decreased risk of atrial fibrillation/flutter in patients with and without chronic kidney disease. Atherosclerosis. 2014;232(1):224–30.
Kawahara T, Nishikawa M, Kawahara C, et al. Atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial. Circulation. 2013;127(23):2327–35.
Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD004816.
Tonelli M, Sacks FM, Cole T, Curhan GC, Cholesterol and Recurrent Events Trial Investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol. 2003;14(6):1605–13.
Stefanec T. The effects of statins on mortality rates among bacteremic patients [letter]. Clin Infect Dis. 2002;34(8):1158.
Almog Y, Shefer A, Novack V, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation. 2004;110(7):880–5.
Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer’s disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc Natl Acad Sci U S A. 2001;98(10):5856–61.
Vaughan TB, Bell DS. Statin neuropathy masquerading as diabetic autoimmune polyneuropathy. Diabetes Care. 2005;28(8):2082.
Baker SK, Tarnopolsky MA. Statin-associated neuromyotoxicity. Timely Top Med Cardiovasc Dis. 2005;9:E26.
Chong PH, Boskovich A, Stevkovic N, et al. Statin-associated peripheral neuropathy: review of the literature. Pharmacotherapy. 2004;24(9):1194–203.
Lo YL, Leoh TH, Loh LM, et al. Statin therapy and small fibre neuropathy: a serial electrophysiological study. J Neurol Sci. 2003;208(1–2):105–8.
Formaglio M, Vial C. Statin induced neuropathy: myth or reality? [in French]. Rev Neurol (Paris). 2006;162(12):1286–9.
West B, Williams CM, Jilbert E, et al. Statin use and peripheral sensory perception: a pilot study. Somatosens Mot Res. 2014;31(2):57–61.
Tierney EF, Thurman DJ, Beckles GL, et al. Association of statin use with peripheral neuropathy in the U.S. population 40 years of age or older. J Diabetes. 2013;5(2):207–15.
Chung SD, Chen CH, Hung SH et al. A population-based study on the association between statin use and sudden sensorineural hearing loss. Otolaryngol Head Neck Surg (in press).
May M, Klein SR. Differential diagnosis of facial nerve palsy. Otolaryngol Clin North Am. 1991;24(3):613–45.
Murakami S, Mizobuchi M, Nakashiro Y, et al. Bell palsy and herpes simplex virus: identification of viral DNA in endoneurial fluid and muscle. Ann Intern Med. 1996;124(1 Pt 1):27–30.
Schirm J, Mulkens PS. Bell’s palsy and herpes simplex virus. APMIS. 1997;105(11):815–23.
Hageman G, Ippel PF, Jansen EN, et al. Familial, alternating Bell’s palsy with dominant inheritance. Eur Neurol. 1990;30(6):310–3.
Kanoh N, Nomura J, Satomi F. Nocturnal onset and development of Bell’s palsy. Laryngoscope. 2005;115(1):99–100.
Chen Y-C, Yeh H-Y, Wu J-C, et al. Taiwan’s National Health Insurance Research Database: administrative health care database as study object in bibliometrics. Scientometrics. 2011;86(2):365–80.
Chung SD, Tsai MC, Lin HC, et al. Statin use and clinical outcomes among pneumonia patients. Clin Microbiol Infect. Epub 2014 Jan 23. doi: 10.1111/1469-0691.12544
Sheu JJ, Kang JH, Lou HY, et al. Reflux esophagitis and the risk of stroke in young adults: a 1-year population-based follow-up study. Stroke. 2010;41(9):2033–7.
Phan T, McLeod G, Pollard JD, et al. Peripheral neuropathy associated with simvastatin. J Neurol Neurosurg Psychiatry. 1995;58(5):625–8.
Ziajka PE, Wehmeier T. Peripheral neuropathy and lipid-lowering therapy. South Med J. 1998;91(7):667–8.
Buajordet I, Madsen S, Olsen H. Statins—the pattern of adverse effects with empahsis on mental reactions. Data from a national and an international database [in Norwegian]. Tidsskr Nor Laegeforen. 1997;117(22):3210–3.
Duits N, Bos FM. Psychiatric disorders with use of simvastatin [in Dutch]. Ned Tijdschr Geneeskd. 1993;137(26):1312–5.
Lechleitner M, Hoppichler F, Konwalinka G, et al. Depressive symptoms in hypercholesterolaemic patients treated with pravastatin [letter]. Lancet. 1992;340(8824):910.
Tuccori M, Montagnani S, Mantarro S, et al. Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management. CNS Drugs. 2014;28(3):249–72.
Schulz JG, Bösel J, Stoeckel M, et al. HMG-CoA reductase inhibition causes neurite loss by interfering with geranylgeranylpyrophosphate synthesis. J Neurochem. 2004;89(1):24–32.
Wood WG, Eckert GP, Igbavboa U, et al. Statins and neuroprotection: a prescription to move the field forward. Ann N Y Acad Sci. 2010;1199:69–76.
Xu X, Gao W, Dou S, et al. Simvastatin inhibited the apoptosis of PC12 cells induced by 1-methyl-4-phenylpyridinium ion via inhibiting reactive oxygen species production. Cell Mol Neurobiol. 2013;33(1):69–73.
Sim FJ, Lang JK, Ali TA, et al. Statin treatment of adult human glial progenitors induces PPAR gamma-mediated oligodendrocytic differentiation. Glia. 2008;56(9):954–62.
Klopfleisch S, Merkler D, Schmitz M, et al. Negative impact of statins on oligodendrocytes and myelin formation in vitro and in vivo. J Neurosci. 2008;28(50):13609–14.
Miron VE, Zehntner SP, Kuhlmann T, et al. Statin therapy inhibits remyelination in the central nervous system. Am J Pathol. 2009;174(5):1880–90.
Garjani A, Andalib S, Ziaee M, et al. Biphasic effects of atorvastatin on inflammation. Pak J Pharm Sci. 2008;21(2):125–30.
Kiener PA, Davis PM, Murray JL, et al. Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. Int Immunopharmacol. 2001;1(1):105–18.
Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63(3):713–21.
Rudski L, Rabinovitch MA, Danoff D. Systemic immune reactions to HMG-CoA reductase inhibitors. Report of 4 cases and review of the literature. Medicine (Baltimore). 1998;77(6):378–83.
Haroon M, Devlin J. A case of ANCA-associated systemic vasculitis induced by atorvastatin. Clin Rheumatol. 2008;27(Suppl 2):S75–7.
Riga M, Kefalidis G, Danielides V. The role of diabetes mellitus in the clinical presentation and prognosis of Bell palsy. J Am Board Fam Med. 2012;25(6):819–26.
Paul R, Stassen LF. Transient facial nerve paralysis (Bell’s palsy) following administration of hepatitis B recombinant vaccine: a case report. Br Dent J. 2014;216(2):69–71.
This study is based, in part, on data from the National Health Insurance Research Database provided by the Bureau of National Health Insurance, Department of Health, Taiwan and managed by the National Health Research Institutes. The interpretations and conclusions contained herein do not represent those of the said agencies.
Sources of Funding
Conflict of interest disclosures
Shih-Han Hung, Li-Hsuan Wang, Herng-Ching Lin, and Shiu-Dong Chung have no conflicts of interest to declare.
An erratum to this article is available at http://dx.doi.org/10.1007/s40264-016-0500-3.
About this article
Cite this article
Hung, SH., Wang, LH., Lin, HC. et al. Association Between Statin Use and Bell’s Palsy: A Population-Based Study. Drug Saf 37, 735–742 (2014). https://doi.org/10.1007/s40264-014-0212-5
- Index Date
- Statin User
- Polymyalgia Rheumatica